Abstract: The invention relates to chimeric vaccine antigens against hepatitis C virus (HCV) comprising selected regions of different antigens of said virus, which are placed in a pre-determined order inside the polypeptide. In addition, said chimeric antigens can include artificially formed specific epitopes for auxiliary T helper lymphocytes. The chimeric antigens and the resulting vaccine compositions are suitable for use in medicine and the pharmaceutical industry, as well as being suitable for prophylactic and/or therapeutic use against HCV. The vaccine compositions of the invention generate a powerful, broad-spectrum immune response against different antigens of the virus, with a minimum number of components.

Abstract: The invention relates to chimeric vaccine antigens against hepatitis C virus (HCV) comprising selected regions of different antigens of said virus, which are placed in a pre-determined order inside the polypeptide. In addition, said chimeric antigens can include artificially formed specific epitopes for auxiliary T helper lymphocytes. The chimeric antigens and the resulting vaccine compositions are suitable for use in medicine and the pharmaceutical industry, as well as being suitable for prophylactic and/or therapeutic use against HCV. The vaccine compositions of the invention generate a powerful, broad-spectrum immune response against different antigens of the virus, with a minimum number of components.

Abstract: Formulation of vaccine antigens, containing as main components: a—) one or several DNA expressing one or several proteins in the immunized individuals and b—) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.

Abstract: Formulation of vaccine antigens, containing as main components: a-) one or several DNA expressing one or several proteins in the immunized individuals and b-) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.

Abstract: A vaccine composition for the therapeutic and prophylactic treatment of Hepatitis C, containing as components the Hepatitis C virus structural proteins in certain proportions and having an enhancer effect in the development of the immune response against the Hepatitis C virus. Combined vaccines against pathogenic entities including this vaccine composition are also described.

Abstract: The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in Picchia pastoris. The formulations of the present invention also comprise the combination of the Hepatitis B surface antigen and other coadministered antigens. The resulting formulations are able to generate potent lymphoprolipherative and cytotoxic responses apart from a remarkable response of specific antibodies, which make them very effective in the treatment of such diseases.

Abstract: Formulation of vaccine antigens, containing as main components: a-) one or several DNA expressing one or several proteins in the immunized individuals and b-) a viral antigen, in appropriate proportions. The novelty of the invention is given by the enhancing effect of at least one component on the immune response generated against the other one.